The board of directors of Hansa Medical has resolved on a directed new issue of ordinary shares, subject to approval by an extraordinary general meeting, whereby Hansa Medical will raise proceeds of approximately SEK 545 million, before issue costs.
The share issue is directed to a number of selected international and Swedish reputable long-only investors and international sector specialist funds, on the basis of an accelerated bookbuilding process conducted by Evercore, RBC Capital Markets and SEB.
Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The company’s shares are admitted to trading on Nasdaq Stockholm.
Vinge’s team has consisted of Dain Hård Nevonen, Erik Sjöman, Joakim Hagberg, Sabina Börjesson and Ramin Baradaran.
